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tBACKGROUND & AIMS: Cigarette smoking has been
implicated in the etiology of esophageal adenocarcinoma,
but it is not clear if smoking is a risk factor for Barrett’s
esophagus. We investigated whether tobacco smoking and
other factors increase risk for Barrett’s esophagus.
METHODS: We analyzed data from 5 case-control stud-
ies included in the international Barrett’s and Esophageal
Adenocarcinoma Consortium. We compared data from
subjects with Barrett’s esophagus (n  1059) with those
from subjects with gastroesophageal reflux disease (gas-
troesophageal reflux disease controls, n  1332), and
opulation-based controls (n  1143), using multivari-
ble logistic regression models to test associations with
igarette smoking. We also tested whether cigarette smok-
ng has synergistic effects with other exposures, which
ight further increase risk for Barrett’s esophagus. RE-
ULTS: Subjects with Barrett’s esophagus were signifi-
antly more likely to have ever smoked cigarettes than the
opulation-based controls (odds ratio [OR]  1.67; 95%
onfidence interval [CI]: 1.04 –2.67) or gastroesophageal
eflux disease controls (OR  1.61; 95% CI: 1.33–1.96).
ncreasing pack-years of smoking increased the risk for
arrett’s esophagus. There was evidence of a synergy be-
ween ever-smoking and heartburn or regurgitation; the
ttributable proportion of disease among individuals who
ver smoked and had heartburn or regurgitation was
stimated to be 0.39 (95% CI: 0.25– 0.52). CONCLU-
IONS: Cigarette smoking is a risk factor for Barrett’s
sophagus. The association was strengthened with in-
reased exposure to smoking until 20 pack-years,
hen it began to plateau. Smoking has synergistic
ffects with heartburn or regurgitation, indicating
hat there are various pathways by which tobacco
moking might contribute to development of Barrett’s
sophagus.
eywords: BEACON; Esophageal Cancer; Population
tudy; Tobacco.
Barrett’s esophagus is a columnar metaplasia of thedistal esophagus associated with a 10- to 55-fold
ncreased risk of esophageal adenocarcinoma.1–7 Barrett’s
esophagus8 –11 and esophageal adenocarcinoma12–14 have
een increasing in incidence, particularly in developed
ountries with predominantly white populations. For ex-mple, in the United States, esophageal adenocarcinoma
n white populations has increased from 0.4 to 3 per
00,000 person-years during the last 35 years—a 650%
ncrease.12,15 This increasing incidence is not solely due to
changes in diagnostic practice, and has been attributed to
temporal changes in exposure to risk factors.16
The known risk factors for Barrett’s esophagus and
esophageal adenocarcinoma are few and include gastro-
esophageal reflux17,18 and increasing body mass index
BMI).19 –21 Cigarette smoking has also been implicated in
the etiology of esophageal adenocarcinoma,22 but whether
his is because smoking is a risk factor for early events in
he carcinogenic pathway (ie, Barrett’s esophagus) or for
ater events, such as the transformation of Barrett’s esoph-
gus to cancer, is unclear, given the conflicting findings of
revious studies of Barrett’s esophagus risk factors, with
ome studies demonstrating a positive association be-
ween Barrett’s esophagus and cigarette smoking18,23–27
and others not.28 –32
The inability to ascertain what, if any, relationship
exists between Barrett’s esophagus and smoking has been
due in part to imprecision rendered by limited numbers of
subjects available for analysis in individual studies. This
limitation has also reduced the ability to discern interac-
tions between exposures; if tobacco smoking does increase
risk of Barrett’s esophagus, it could do so primarily
through genotoxic mechanisms or by promoting gastro-
esophageal reflux disease (GERD). Refining our under-
standing of the potential mechanism(s) of association is
important with regard to the efficacy of preventative ac-
tions.
To better understand the relationship between Barrett’s
esophagus and one of its few potentially modifiable risk
factors, we assessed whether cigarette smoking was asso-
ciated with Barrett’s esophagus and the potential mecha-
nism of association by pooling, harmonizing, and analyz-
ing individual patient data from 5 case-control studies in
Abbreviations used in this paper: BEACON, Barrett’s and Esophageal
Adenocarcinoma Consortium; BMI, body mass index; CI, conﬁdence
interval; FINBAR, Factors Inﬂuencing the Barrett’s/Adenocarcinoma
Relationship; GERD, gastroesophageal reﬂux disease; OR, odds ratio.
© 2012 by the AGA Institute
0016-5085/$36.00doi:10.1053/j.gastro.2011.12.049
st
i
S
d
a
F
i
B
b
w
e
t
t
c
i
(
p
s
h
i
i
e
v
o
h
v
o
G
v
o
t
p
i
C
LI
N
IC
A
L
A
T
April 2012 SMOKING AND BARRETT’S ESOPHAGUS 745the international Barrett’s and Esophageal Adenocarci-
noma Consortium (BEACON, http://beacon.tlvnet.net/).
Materials and Methods
Study Population
The BEACON consortium was formed in 2005 with
support from the US National Cancer Institute. It is composed
of investigators from around the world and brings together
population-based case-control and cohort studies of esophageal
adenocarcinoma and Barrett’s esophagus. The primary objec-
tives of BEACON are to facilitate well-powered, combined inves-
tigations of risk factors in relation to these diseases, as well as
help development of new studies of etiology, prevention, and
survival.
The following are 5 Barrett’s esophagus case-control studies
included in this BEACON analysis: the Factors Influencing the
Barrett’s/Adenocarcinoma Relationship (FINBAR) study based
in Ireland33; Epidemiology and Incidence of Barrett’s Esophagus
tudy nested within Kaiser Permanente Northern California34;
Study of Reflux Disease, based in western Washington state35;
Study of Digestive Health based in Brisbane, Australia26; and
Epidemiologic Case-Control Study of Barrett’s Esophagus based
at The University of North Carolina at Chapel Hill, NC. For
comparison with Barrett’s esophagus cases, 2 control groups
were available: GERD and population-based. There are advan-
tages for each of these comparison groups. GERD controls
represent the population undergoing endoscopy from which
Barrett’s esophagus cases are diagnosed. Therefore, comparisons
between these 2 groups are less affected by potential ascertain-
ment bias than comparisons between Barrett’s esophagus cases
and population-based controls because it inherently controls for
known and unknown potentially confounding factors associ-
ated with being referred for and undergoing an endoscopic
procedure. In addition, because most cases are identified in the
course of investigating gastroesophageal reflux, the use of GERD
controls, to some degree, inherently adjusts for the presence,
although not severity, of symptomatic gastroesophageal reflux.
The major advantage of the population-based control group is
that it enables the assessment of gastroesophageal reflux as both
an effect-measure modifier and independent risk factor, and is
also representative of the local population from which the Bar-
rett’s esophagus cases are referred and diagnosed. Studies that
have conducted endoscopy on random samples of the general
population provide more in-depth information on the relative
advantages and disadvantages of each of these 2 control
groups.36,37 All 5 studies contributed individual patient data to
he GERD control group and 4 of the studies contributed
ndividual patient data to the population-based control group.
tudy-specific definitions of the case and control groups are
etailed in Table 1.
In total, the 5 studies provided 1320 cases of Barrett’s esoph-
gus, 1659 GERD controls, and 1434 population-based controls.
or this analysis, and if a study provided such data, we excluded
ndividuals who had ever smoked pipe tobacco or cigars (156
arrett’s esophagus cases, 132 GERD controls, 153 population-
ased controls) because comparing cigarette smokers with those
ho do not use other forms of tobacco provides a more accurate
stimate of the effect of cigarette smoking. Ever smoking pipe
obacco or cigars was defined as meeting a study-specific low
hreshold exposure (a period of 6 months or 20 times during
the life-course). Because of the relatively small number of non-
white Barrett’s esophagus cases remaining (17 black, 31 His-panic, 39 other, and 18 missing), we restricted our analysis to
white study participants. After exclusions, there remained 1059
Barrett’s esophagus cases, 1332 GERD controls, and 1143 pop-
ulation-based controls for analysis. Data acquisition and data
pooling for each study were approved by the Institutional Re-
view Board or Research Ethics Committee of the institute(s)
sponsoring the study.
Analytic Variables
The primary exposure variables were cigarette smoking
status (ever vs never) and total cigarette smoking exposure
(pack-years; 0, 15, 15–29, 30 – 44, 45). Additional exposure
variables included duration of cigarette smoking (30 years,
30 years), cigarette smoking intensity (1, 1, and 1 packs/
day), age of cigarette smoking initiation (17, 17 years), and
duration of cigarette smoking cessation (20 years, 20 years).
Cigarette smoking intensity and cigarette smoking duration in
the University of North Carolina-Chapel Hill study were ascer-
tained in categories and were recoded to the median of the
categories using the distributions of the other 4 studies com-
bined. Ever cigarette smoking was defined as either low thresh-
old exposures (100 cigarettes, 20 packs of cigarettes, 1 ciga-
rette a day for 6 months) or by asking whether the patient had
ever smoked. The following covariates were assessed for inclu-
sion in regression models: age; sex; BMI (weight divided by
square of height [kg/m2]); education; alcohol; fat, and trans-fat
onsumption; calories per day; meat, vegetable, and fruit serv-
ngs per day; fiber consumption; heartburn, and regurgitation
population-based control models only); esophagitis; Helicobacter
ylori seropositivity; hiatal hernia; and medication use (ie, non-
teroidal anti-inflammatory drugs, antacids, proton pump in-
ibitors, and H2-receptor antagonists). A covariate was included
n the fully adjusted models if it altered an estimate by 10% or
t was considered a known confounder (eg, age, sex, BMI, and
ducation).
Statistical Analysis
We used a 2-step analytic approach. First, study-specific
odds ratios (ORs) and 95% confidence intervals (CIs) for an
exposure– outcome relationship were estimated from multivari-
able logistic regression models. Second, the study-specific ORs
were combined using fixed-effects and random-effects meta-
analytic models to generate summary ORs; both approaches
gave similar estimates of association, so we present the random-
effects models only, as such models are usually more conserva-
tive.38 A study was excluded from the second-step of a specific
ariable’s analysis if the logistic regression model failed because
f instability. The I2 value and its 95% uncertainty interval were
used to estimate the percentage of total variation across studies
due to heterogeneity.39 An I2 statistic of 0% indicates no observed
eterogeneity that cannot be attributed to chance, and larger
alues indicate increasing heterogeneity.
Exposure variables were assessed in relation to the outcomes
f Barrett’s esophagus using the following comparison groups:
ERD controls and population-based controls. Continuous
ariables were categorized to allow for nonlinear effects, for ease
f interpretation, and to reduce the effect of any outliers; excep-
ions to this were the use of continuous variables for trends,
roduct-terms, and spline models. Minimally adjusted models
ncluded the covariate’s age (50, 50 –59, 60 – 69, 70 years) and
sex. Fully adjusted models also included BMI (18.5, 18.5–24,
25–29, 30 –34, 35–39, 40) and education (categorical: school
only, tech/diploma, university; unavailable and so unadjusted
Table 1. Recruitment, Criteria, and Numbers for Analysis in Each of the Barrett’s Esophagus Case-Control Studies
Study Location
BE
cases, n Barrett’s esophagus case definition
GERD
controls, n GERD control definitions
Population-
based
controls, n Population-based control definition
KPNC Northern California,
USA
187 Incident cases recruited from KPNC,
October 2002 to September
2005. SIM and any length of
macroscopic BE. Exclusions:
gastric-type metaplasia only,
indicative biopsy from
squamocolumnar junction.
172 Prior to their index date: a GERD-related
diagnosis code (ICD-9: 530.11 [reflux
esophagitis] or 530.81
[gastroesophageal reflux]); a
prescription 90-day supply of an
H2RA or PPI in the previous year;
recent esophagogastroduodenoscopy
that was negative for esophageal
columnar metaplasia (macroscopic or
histologic) of any type. Frequency
matched on age at index date, sex,
and geographic region to the
distribution of BE cases. Exclusions:
previous BE diagnosis.
185 KPNC members without an electronic
diagnosis of BE at the time the BE
cases were identified, frequency
matched on age at index date,
sex, and geographic region to the
distribution of BE cases.
Study of Digestive
Health
Brisbane,
Queensland,
Australia
362 Incident cases of BE, or of
dysplasia in previously diagnosed
BE, recruited from 2 major private
pathology laboratories and the
single public pathology laboratory
serving metropolitan Brisbane,
Australia, February 2003–June
2006. SIM and any length of
macroscopic BE.
287 Acute inflammatory changes on
histology consistent with
gastroesophageal reflux. Exclusions:
Any other major pathology identified
on endoscopy/histology.
562 Randomly selected from the
Australian Electoral roll. Frequency
matched on age and sex to a case
series. Control participants had to
reside within the same
geographical region as the BE
cases and GERD controls.
Study of Reflux
Disease
Washington, USA 149 Incident cases recruited from 5
community gastroenterology
clinics, October 1997–September
2000. Endoscopy referral due to
chronic GERD symptoms. SIM.
347 Referred for endoscopy due to reflux
symptoms, but negative for SIM.
Frequency-matched on the month of
biopsy and clinic to the distribution of
BE cases.
172 Selected from geographic areas in
close proximity to those of BE
cases using a modified version of
the Waksberg random-digit dialing
method. Individually matched to
BE cases on age (3 years) and
sex.
FINBAR Northern Ireland
and Republic of
Ireland
187 Incident and prevalent cases
recruited from the island of
Ireland, March 2002–December
2004. SIM and 3 cm of
macroscopic BE. Exclusions:
dysplasia.
217 Erosive esophagitis (incident and
prevalent diagnoses):
macroscopically diagnosed (grades
2–4 in the Savary Miller/Hetzel-Dent
classification/grades B, C, or D in
the LA classification), recruited from
Northern Ireland, September 2004–
July 2005. Exclusions: BE,
macroscopic or histologic evidence of
infection, dysmotility, gastric outlet
obstruction. Frequency matched on
age and sex to the distribution of EA
patients.
224 Northern Ireland: selected at random
from General Practice Master
Index of each province. Republic
of Ireland: selected at random
from 4 general practices to reflect
the urban/rural distribution of EA
patients in the Republic of Ireland.
Frequency matched on age and
sex to the distribution of EA
patients. Recruited from the island
of Ireland between March 2002–
December 2000.
UNC-Chapel Hill North Carolina,
USA
174 Incident and prevalent cases
recruited from an endoscopy
clinic-based study between 2001
and 2006. SIM and any length of
macroscopic BE.
309 GERD diagnosed by a physician:
referred for endoscopy due to reflux
symptoms, but negative for
macroscopic BE and SIM. Sampled in
2:1 ratio to BE subjects.
0 NA
Total 1,059 1332 1143
BE, Barrett’s esopagus; EA, esphageal adenocarcinoma; H2RA, H2-receptor antagonists; ICD-9, International Classification of Diseases, 9th revision; KPNC, Kaiser Permanente Northern California; NA, not available; PPI, proton
pump inhibitors; SIM, specialized intestinal metaplasia.
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April 2012 SMOKING AND BARRETT’S ESOPHAGUS 747for in University of North Carolina-Chapel Hill study). These
models were also stratified by sex, BMI, and heartburn or regur-
gitation (population-based control comparisons only) to assess
relationships (ORs) for effect–measure modification, with P val-
ues estimated via random effects meta-analysis of study-specific
estimated effects of product-terms (eg, ever-smoke sex). Heart-
urn was generally described to the patient as having ever expe-
ienced burning pain or discomfort behind the breast bone, and
egurgitation was generally described as food or stomach fluid
oming back up into the mouth accompanied with a sour-taste;
aiser Permanente Northern California excluded symptoms
ithin 1 year before diagnosis of Barrett’s esophagus, and FIN-
AR excluded symptoms within 5 years. In addition, FINBAR
equired symptoms to be frequent (50 times per year/about
nce a week). Models of the additional exposures (cigarette
moking duration, intensity, initiation, and cessation) were also
djusted for total exposure (pack-years of cigarette smoking);
ecause these variables contribute to total exposure, association
esting without adjustment for total exposure could be mislead-
ng.40,41
Spline models42 were used to generate plots of the relation-
hip between continuous pack-years of cigarette smoking and
isk of Barrett’s esophagus compared with each control group
nd adjusted for age, sex, BMI, and study using the pooled
ataset of individual patient data. Restricted cubic spline models
llow for easy visualization of nonlinear relationships between
n exposure and an outcome43,44—in this case, cigarette smoking
nd Barrett’s esophagus. These models were plotted using a
inear scale on the x-axis (pack-years of cigarette smoking) and a
ogarithmic (base 10) scale on the y-axis (OR).
To determine whether cigarette smoking biologically interacts
ith other exposures in relation to risk of Barrett’s esophagus,
e tested for departure from additivity. Positive departure from
dditivity implies that the number of cases attributable to 2
xposures in combination is larger than the sum of the numbers
f cases that would be caused by each exposure separately. The
ovariates tested for biological interaction with ever-cigarette
moking were BMI (27.5, 27.5), heartburn and regurgitation
population-based control comparisons only), alcohol, H pylori,
nd nonsteroidal anti-inflammatory drugs. For each combina-
ion of variables, we generated 4 exposure categories; using BMI
s an example: A  never-smoker, low BMI; B  smoker, low
Table 2. Descriptors of Participants Selected for Analysis of C
International BEACON Consortium
Variable
BE
(n  1059)
G
Age, y, mean (SD) 59 (12)
Male sex, % (95% CI) 68 (66–71)
Education (college or university), % (95% CI) 66 (63–69)
Body mass index, mean (SD) 28.4 (5.1) 2
Heartburn, % (95% CI) 83 (81–86)
Regurgitation, % (95% CI) 76 (74–79)
Heartburn or regurgitation, % (95% CI) 91 (89–93)
Alcohol, % (95% CI) 77 (75–80)
igarette smoking, % (95% CI) 63 (60–65)
ack-years, mean (SD) 31 (26)
igarettes/day, mean (SD) 22 (14)
ears smoked, mean (SD) 26 (14)
OTE. P values were determined using the t test for continuous varia
are statistically significant at   .05.
SD, standard deviation.BMI; C  never-smoker, high BMI; D  smoker, high BMI.
These variables were modeled in the pooled dataset of individual
patient data using logistic regression adjusted for age, sex, BMI,
education, and study. Assuming that the OR approximates the
relative risk, the output from these models was used to estimate
3 interaction statistics: interaction contrast ratio, attributable
proportion, and synergy index.45,46 When the interaction con-
trast ratio and attributable proportion  0 and synergy index 
1, there is evidence for departure from additivity (biological
interaction). Interaction contrast ratio is the excess risk due to
interaction relative to the risk without either exposure. Attrib-
utable proportion is the proportion of disease attributable to
interaction among individuals with both exposures. Synergy
index is the ratio of the observed excess risk in individuals
exposed to both factors relative to the expected excess risk,
assuming that both exposures are independent risk factors (ie,
under the assumption of no additive interaction). Confidence
intervals for these metrics were estimated using the delta
method.45
All analyses were performed using STATA software, version
11.1 (StataCorp LP, College Station, TX). All statistical tests were
2-sided and P values 0.05 were considered to be statistically
significant.
Results
Descriptors of cases and controls included in the
analysis are shown in Table 2. The population-based con-
trol distributions were more similar to the cases in terms
of age and sex than the GERD controls, and this is
because 3 of the 4 studies with population-based controls
matched on these variables to the Barrett’s esophagus case
group; GERD controls were matched to the Barrett’s
esophagus group on age and sex in only 1 study (Table 1).
However, in other respects, such as BMI and alcohol,
GERD controls had distributions more similar to the
Barrett’s esophagus group compared with the population-
based control group.
Table 3 shows the estimates of association between
cigarette smoking variables and Barrett’s esophagus, com-
pared with both GERD controls and population-based
rette Smoking in Relation to Barrett’s Esophagus in the
controls
1332) P value
Population-based controls
(n  1143) P value
(14) .001 59 (12) .874
(50–55) .001 64 (62–67) .039
(61–67) .243 67 (64–69) .763
(5.3) .759 27.6 (5.1) .001
NA NA 47 (44–50) .001
NA NA 44 (42–47) .001
NA NA 57 (54–60) .001
(73–78) .328 82 (80–84) .005
(47–52) .001 49 (46–51) .001
(25) .001 29 (29) .355
(14) .007 21 (15) .169
(14) .001 25 (14) .330
and the Pearson 2 test for categorical variables. P values in italicsiga
ERD
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748 COOK ET AL GASTROENTEROLOGY Vol. 142, No. 4controls. Subjects with Barrett’s esophagus were signifi-
cantly more likely to have ever-smoked cigarettes than
both the population controls (OR  1.67) and the GERD
controls (OR  1.61), although the GERD study-specific
stimates appeared to be less heterogeneous (I2  11%,
95% uncertainty interval: 0 – 81%) than estimates from
population-based control models (I2  82%, 95% uncer-
ainty interval: 54 –93%). Increasing pack-years of cigarette
moking was associated with an increasing OR for Bar-
ett’s esophagus compared with both control groups (Ta-
le 3, Figure 1), although the risk relationship was not
trictly linear in the categories used for assessment; the
Rs for Barrett’s esophagus were approximately 1.5 for
oth 15 and 15 to 29 pack-years of smoking exposure
roups, and approximately 2 for each of the higher expo-
ure groups (ie, 30 – 44 and 45 pack-years of smoking)
ompared with each of the control groups and using
ever smokers as the referent. The spline models, shown
n Figure 2, are somewhat more indicative of a linear
elationship—at least until approximately 20 pack-years of
moking—and this did not change when never-smokers
ere excluded. Conversely, the P value for trend for pack-
ears of smoking was statistically significant only when
Table 3. Fully Adjusted Odds Ratios and 95% Confidence Inte
of Barrett’s Esophagus
n
Population co
n OR 95% CI
ver cigarette smoking
No 325 580 Referent
Yes 548 541 1.67 1.04–2.67
ack-years of smoking
0 (never-smokers) 325 580 Referent
15 185 205 1.59 1.02–2.47
15 to 30 129 134 1.44 0.78–2.69
30 to 45 102 85 1.99 1.21–3.29
45 132 118 1.92 1.05–3.51
P for trend 873 1122 0.057
P for trend excluding never
smokers
548 542 0.193
moking duration,a y
30 328 338 Referent
30 220 204 0.95 0.68–1.35
Smoking intensity,a packs per day
1 207 230 Referent
1 163 151 1.16 0.79–1.68
1 178 161 1.02 0.63–1.65
Age of smoking initiation,a y
17 259 247 Referent
17 289 294 0.96 0.70–1.32
Smoking cessation,a y
20 193 164 Referent
20 205 229 0.91 0.64–1.31
NOTE. Results were adjusted for age (categorical:50, 50–59, 60–69
40), and education (except University of North Carolina).
UI, uncertainty interval.
aAlso adjusted for pack-years of smoking (categorical: 15, 15–29, 3ever smokers were included for analysis (Table 3). Lastly,he additional cigarette smoking variables of duration,
ntensity, age of initiation, and duration of cessation were
ot associated with Barrett’s esophagus after adjustment
or total exposure (Table 3).
As shown in Figure 1, there were moderate-to-high
evels of heterogeneity that were predominantly the prod-
ct of the relatively lower estimates generated by the
INBAR study. When the FINBAR study was excluded,
he summary ORs from the fully adjusted models slightly
ncreased and heterogeneity (I2 values) decreased (popula-
ion-based controls: ORever-smoke  2.09; 95% CI: 1.54 –2.83;
2  44%; OR15  1.93; 95% CI: 1.36 –2.74; I2  30%;
R15–29  1.75; 95% CI, 0.93–3.30; I2  68%; OR30–44 
.49; 95% CI: 1.70 –3.65; I2  0%; OR45  2.57; 95% CI:
1.79 –3.67; I2  0%; GERD controls: ORever-smoke  1.75;
95% CI: 1.43–2.15; I2  0%; OR15  1.32; 95% CI: 0.95–
1.84; I2  38%; OR15–29  1.62; 95% CI: 1.09 –2.41; I2 
5%; OR30–44  2.87; 95% CI: 1.88–4.38; I2  19%; OR45 
.12; 95% CI: 1.50–3.00; I2  0%).
The stratified models tested whether the effect of a
single exposure in relation to Barrett’s esophagus was
modified by another variable. When stratified by sex, the
estimates for ever-smoking and categories of pack-years,
ls for the Association Between Cigarette Smoking and Risk
Barrett’s esophagus
ls
n
GERD controls
2 (95% UI) n n OR 95% CI I2 (95% UI) n
382 643 Referent
2 (54–93) 4 638 635 1.61 1.33–1.96 11 (0–81) 5
382 643 Referent
4 (0–88) 4 208 269 1.49 1.02–2.18 57 (0–84) 5
6 (33–91) 4 137 136 1.48 1.04–2.12 27 (0–71) 5
9 (0–83) 4 124 91 2.24 1.14–4.40 75 (38–90) 5
0 (12–89) 4 155 129 1.69 1.11–2.59 49 (0–81) 5
4 1006 1268 0.009 5
4 619 625 0.170 5
352 395 Referent
0 (0–81) 4 267 230 0.98 0.69–1.40 0 (0–76) 5
225 277 Referent
3 (0–85) 4 188 170 1.02 0.71–1.46 0 (0–78) 5
0 (0–53) 4 206 178 0.97 0.44–2.13 59 (0–85) 5
258 239 Referent
1 (0–88) 4 287 269 0.96 0.65–1.41 44 (0–81) 4
224 232 Referent
0 (0–76) 4 227 206 1.24 0.86–1.78 0 (0–58) 5
70), sex, body mass index (categorical:25, 25–29, 30–34, 35–39,
44, 45).rva
ntro
I
8
6
7
4
7
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April 2012 SMOKING AND BARRETT’S ESOPHAGUS 749men (ORever-smoke  1.81; 95% CI: 1.43–2.30; I2  0%) than
omen (ORever-smoke  1.32; 95% CI: 0.91–1.92; I2  31%)
ompared with GERD controls (Supplementary Table 1).
lthough ever-smoking stratified by sex was statistically
ignificant (P .041), pack-years of cigarette smoking was
ot (P  .5). Estimates of risk were not statistically dif-
ferent by sex when using population-based controls as the
comparison group. Analyses stratified by BMI indicated
that associations between cigarette smoking and Barrett’s
esophagus might be stronger in those with a lower BMI
(P .046), when using the population-based controls as the
comparison group, although no pattern by BMI was dis-
cernable when compared with GERD controls (P  .9;
Supplementary Table 2). Analyses stratified by heartburn
and regurgitation provided higher estimates for ever-
smoking and pack-years of smoking in relation to Bar-
rett’s esophagus in individuals without such symptoms
Figure 1. Forest plots of the relationship between increasing categ
opulation-based controls and (B) GERD controls. Each study’s est
epresenting 95% CIs. The gray box overlaying each estimate represents
re designated by the diamonds that follow each subgroup; the widths o
California; UNC, University of North Carolina.
Figure 2. Spline plots of the re-
lationship between increasing
categories of cigarette smoking
and Barrett’s esophagus com-
pared with (A) population-based
controls and (B) GERD controls.
The solid line represents the es-
imate of the OR, and the broken
lines on either side represent
95% CIs.(ORever-smoke  3.35; 95% CI: 1.55–7.26; I2  0%) compared
with individuals who reported symptoms (ORever-smoke 
.99; 95% CI: 1.50 –2.65; I2  23%) when using popula-
ion-based controls as the referent, although these differ-
nces were not statistically significant (Supplementary
able 3).
Table 4 shows the results from the interaction models
o test departures from additivity, which are considered as
vidence for the existence of biologic interaction. Unlike
ffect-measure modification of ORs across strata of a
econd variable, each with an independent referent group,
nteraction models simultaneously tested the effects of 2
xposures in relation to Barrett’s esophagus to assess
hether there were synergistic effects. We found evidence
or biologic interaction between ever-cigarette smoking
nd heartburn/regurgitation, with an attributable propor-
ion due to interaction among those exposed to both risk
s of cigarette smoking and Barrett’s esophagus compared with (A)
te is represented by the corresponding black square with the arms
weight that it contributes to the pooled estimate. The pooled estimates
diamonds represent the 95% CIs. KPNC, Kaiser Permanente Northernorie
ima
the
f the
st ra
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750 COOK ET AL GASTROENTEROLOGY Vol. 142, No. 4factors of 0.39 (95% CI: 0.25– 0.52) (Table 4). Compared
with the unexposed referent of population controls with-
out heartburn/regurgitation who also never smoked, the
ORs for Barrett’s esophagus for each exposure category
were 9.35 (95% CI: 6.08 –14.39) for those exposed to heart-
burn/regurgitation only, 1.71 (95% CI: 1.04 –2.80) for
those exposed to smoking only, and 16.47 (95% CI: 10.73–
25.29) for those exposed to both.
Discussion
The relationship between cigarette smoking and
Barrett’s esophagus is unclear. Given the high prevalence
of smoking and its status as one of the few potentially
modifiable risk factors for Barrett’s esophagus, this rela-
tionship requires a more complete understanding. In this
analysis of individual patient data from 5 studies within
the international BEACON consortium, we found evi-
dence for associations between ever-smoking and increas-
ing pack-years with increased risk of Barrett’s esophagus.
We did not find independent associations with related
exposure variables, such as duration of smoking or the
mean number of cigarettes smoked per day, suggesting
that the cumulative exposure to cigarette smoke is the
most important exposure in this relationship. We also
found tentative evidence that the relationship between
cigarette smoking and Barrett’s esophagus might be
stronger in men, which could indicate sex differences in
the role of smoking with respect to pathogenesis of Bar-
rett’s esophagus. Lastly, evidence for biological interaction
between heartburn/regurgitation and cigarette smoking
suggests varied mechanistic effects of cigarette smoking in
the development of Barrett’s esophagus.
Our understanding of the relationship between ciga-
rette smoking and Barrett’s esophagus has been hampered
by inconsistent data from studies too small to fully assess
the issue; some studies have found evidence for an asso-
ciation using population-based controls,23,24 endoscopy-
Table 4. Interaction Statistics for Departure From Additivity
Variables tested for interaction with ever-smoking
ICR (95
(null hypoth
Barrett’s esophagus vs population-based controls
BMI 0.06 (0.5
Heartburn 2.75 (0.67
Regurgitation 4.58 (2.16
Heartburn or regurgitation 6.41 (2.71
Alcohol 0.24 (0.9
H pylori 0.16 (0.7
NSAID 0.31 (0.1
Barrett’s esophagus vs GERD control
BMI 0.26 (0.7
Alcohol 0.36 (0.0
H pylori 0.07 (0.7
NSAID 0.42 (0.0
NOTE. Italicized estimate and confidence interval represents statistic
AP, attributable proportion due to interaction; ICR, interaction contrasnegative controls,18,25 or GERD controls,18,28 –30 and othertudies have not found evidence for a relationship.47–50
The analysis presented here is much larger than any of
these previous studies, and this larger sample size pro-
vided for greater statistical power and greater precision of
risk estimates. In addition, the availability of GERD con-
trols and population-based controls allowed for compar-
ison with the source population undergoing endoscopy
and the general population, respectively, with the latter
also enabling assessment of heartburn/regurgitation as a
potential effect–measure modifier and as a potential syn-
ergistic risk factor. A particular strength of the study is its
use of pooled individual patient data through a large
international consortium; this method provides more
comparable statistical estimates than standard meta-anal-
ysis, which pool published ORs that differ in their variable
definitions and the confounders included. Therefore, the
results of this analysis are the strongest available data to
date regarding cigarette smoking as a risk factor for Bar-
rett’s esophagus.
Barrett’s esophagus is the recognized precursor lesion
of esophageal adenocarcinoma and, if cigarette smoking
was a risk factor for Barrett’s esophagus, one can expect to
observe an association between smoking and esophageal
adenocarcinoma as well. Studies of this malignancy com-
pared with population-based or hospital controls also
provide evidence for an association with cigarette smok-
ing,50 –55 including a recent pooled esophageal adenocar-
cinoma analysis from the international BEACON group.22
Given the concordance of these data, associations between
cigarette smoking and Barrett’s esophagus, as well as
cigarette smoking and esophageal adenocarcinoma, are
likely to be real and, given the high prevalence of the
exposure, might account for a large proportion (40%) of
esophageal adenocarcinomas.56 It has not been known
where smoking acts in the biological pathway. The cur-
rent data suggest that smoking is associated with the risk
Departure from additivity
CI)
s  0)
AP (95% CI)
(null hypothesis  0)
S (95% CI)
(null hypothesis  0)
0.69) 0.03 (0.24 to 0.29) 1.05 (0.64 to 1.71)
.82) 0.27 (0.10 to 0.44) 1.43 (1.10 to 1.86)
.00) 0.41 (0.27 to 0.55) 1.82 (1.38 to 2.40)
0.10) 0.39 (0.25 to 0.52) 1.71 (1.34 to 2.18)
0.49) 0.18 (0.72 to 0.35) 0.59 (0.17 to 1.99)
1.11) 0.06 (0.32 to 0.45) 1.12 (0.54 to 2.35)
0.77) 0.20 (0.09 to 0.50) 2.55 (0.23 to 28.62)
0.20) 0.20 (0.55 to 0.16) 0.54 (0.20 to 1.51)
0.78) 0.27 (0.06 to 0.60) —
0.63) 0.05 (0.56 to 0.46) 0.83 (0.18 to 3.85)
0.86) 0.27 (0.00 to 0.55) 5.22 (0.05 to 561.36)
ignificance (P  .05).
tio; NSAID, nonsteroidal anti-inflammatory drugs; synergy index.%
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April 2012 SMOKING AND BARRETT’S ESOPHAGUS 751Most of our primary exposure analyses had moderate to
high levels of heterogeneity, an effect predominantly
caused by the lower estimates of association from the
FINBAR study.33 Omission of this study reduced the
eterogeneity and had minimal effects on the summary
isk estimates attained, reinforcing the conclusions
rawn. It is not known why the associations between
moking and Barrett’s esophagus were lower in the Irish
tudy population; the proportion of population-based
ontrols that reported ever smoking was higher (55%)
han the other studies (45– 47%), but this slightly higher
ate is insufficient to mask the association evidenced in
he other studies. In addition, the distribution of pack-
ears of cigarette smoking was similar across control
roups and studies, and provision of individual patient
ata enabled similar confounding structures to be con-
tructed for study-specific models. FINBAR’s inclusion
riteria did restrict recruitment of patients to those with
ong-segment Barrett’s esophagus (3 cm; Table 1); a
riterion not used by the other 4 studies included in this
nalysis. However, this is unlikely to have led to lower
stimates of association, given that a previous analysis of
aiser Permanente Northern California data evidenced a
tronger association of cigarette smoking with long-seg-
ent Barrett’s esophagus (OR  1.72; 95% CI: 1.12–2.63)
compared with that for short-segment Barrett’s esopha-
gus (3 cm; OR  1.19; 95% CI: 0.76 –1.85).31 It remains
unexplained why the FINBAR estimates of association
were lower relative to the other studies included in this
pooled analysis.
Analyses stratified by sex suggested that cigarette smok-
ing might be a stronger risk factor for Barrett’s esophagus
among men than among women. However, this relation-
ship was only observed when assessing ever cigarette
smoking in Barrett’s esophagus cases compared with
GERD controls; analyses of pack-years of cigarette smok-
ing and comparisons with population-based controls were
null. Given the known genotoxic effects of tobacco smoke,
evidence that effects of cigarette smoking are similar in
men and women,57 and the number of tests conducted, we
elieve this result represents a chance finding.
Interaction analyses indicated that heartburn/regurgi-
ation symptoms and ever smoking biologically interact
n the risk of Barrett’s esophagus—the attributable pro-
ortion of disease among individuals exposed to these 2
actors was estimated to be 0.39 (95% CI: 0.25– 0.52).
iological interaction of these variables in this setting is
lausible, given evidence that tobacco smoke might not
nly have direct genotoxic effects,58 but might also induce
ransient lower esophageal sphincter relaxations,59 – 61 in-
creasing the likelihood, length, and severity of gastro-
esophageal reflux, a major risk factor for Barrett’s18 and
the sequela, esophageal adenocarcinoma.17 Interaction be-
tween gastroesophageal reflux symptoms and smoking
has been reported previously for Barrett’s esophagus with
dysplasia26 and for esophageal adenocarcinoma.62
There were several strengths of this analysis. First, the
consortial approach enabled generation of the largest re-ported cohort of subjects with Barrett’s esophagus in the
world’s literature, upon which risk factor analysis has been
performed. The large size of the pooled database enabled
more precise estimates of association than previous studies,
particularly in stratified analyses, spline models, and assess-
ment of interaction. Second, although pooling and har-
monization of data is a substantial undertaking and
requires expertise, time, and resources, individual pa-
tient data allows for many benefits over meta-analysis
of published estimates, including building consistent
models across studies, studying novel questions includ-
ing interaction, and using novel methods of analysis such
as splines. Third, the availability of 2 control groups for
comparison, that is, population-based and GERD, allows
us to postulate where risk factors might be active in the
pathogenesis of Barrett’s esophagus. This is important
because it is feasible that a significant proportion of the
population-based control group might unknowingly have
Barrett’s esophagus,63 although such misclassification
ould bias results toward the null.
Limitations of this analysis include the moderate-to-
igh levels of heterogeneity for some analyses. Although
onstituents of tobacco smoke have changed over time,64
the studies included in this analysis recruited incident
cases and controls during a similar period (1997–2006).
Regardless, constituents of tobacco smoke are likely to
have differed geographically as is population susceptibil-
ity to genotoxic exposures. The unexplained heterogeneity
does warrant a cautious interpretation of summary esti-
mates, although associations were largely consistent in a
majority of studies included, and similar summary esti-
mates with low heterogeneity were estimated when the
study that was the source of the most heterogeneity was
omitted from analysis. Another limitation is the possibil-
ity of recall bias, given the case-control design of the
included studies, although the intensity and duration of
smoking are usually recalled relatively reliably.65 Lastly, we
did not adjust for dietary variables in this analysis; al-
though previous studies suggest that diet has minimal
effects on relationships between smoking and Barrett’s
esophagus, there remains the possibility of residual con-
founding through diet and other exposures.
In conclusion, cigarette smoking is a risk factor for
Barrett’s esophagus, with adjusted ORs for multiple
measures of association in the 1.5 to 2 range. The
association appears to strengthen with increased expo-
sure to cigarette smoking until approximately 20 pack-
years, where it begins to plateau. If smoking is a caus-
ative agent of Barrett’s esophagus, it is an attractive
modifiable risk factor, especially in high-risk groups
such as elderly, obese males with GERD symptoms. In
addition, because the origins of Barrett’s esophagus are
poorly understood, a better understanding of its risk
factors and their biological interactions might allow
inference of the biological mechanisms involved in the
nascent stages of Barrett’s esophagus. The evidence we
present for a biological interaction between smoking
and heartburn/regurgitation suggest that cigarette
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
C
LIN
IC
A
L
A
T
752 COOK ET AL GASTROENTEROLOGY Vol. 142, No. 4smoking has multifaceted effects in the development of
this precancerous metaplasia.
Supplementary Material
Note: To access the supplementary material
accompanying this article, visit the online version of
Gastroenterology at www.gastrojournal.org, and at doi:
10.1053/j.gastro.2011.12.049.
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